Cross-linked hyaluronic acid sub-micron particles: In vitro and in vivo biodistribution study in cancer xenograft model

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 6, 2013, Pages 1473-1481

  Rosso, F ^a   Quagliariello, V ^a,b   Tortora, C ^a   Di Lazzaro, A ^b   Barbarisi, A ^a   Iaffaioli, R V ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS TISSUES; COMPETITIVE ASSAYS; GLUTARALDEHYDE CROSS-LINKING; MORPHOLOGICAL ANALYSIS; PROSTATE CANCER CELL LNCAP; SIZE MEASUREMENTS; SUB-MICRON PARTICLES; SYSTEMIC ADMINISTRATION;

CELL CULTURE; DISEASES; ELECTRON MICROSCOPY; FLUORESCENCE; FLUOROPHORES; MAMMALS; ORGANIC ACIDS; TISSUE;

HYALURONIC ACID;

FLUORESCEIN ISOTHIOCYANATE; GLUTARALDEHYDE; HYALURONIC ACID; TETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; ELECTRON MICROSCOPY; EMULSION; ENDOCYTOSIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGHT SCATTERING; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; CROSS-LINKING REAGENTS; DIFFUSION; HYALURONIC ACID; KINETICS; MALE; MATERIALS TESTING; MICE; NANOCAPSULES; ORGAN SPECIFICITY; PARTICLE SIZE; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

MUS;

EID: 84879102904     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-4895-4     Document Type: Article

References (35)

1. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information rich system. Eur J Cell Biol. 2006;85:699-715.
2. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol. 1995;154:5345-55.
3. Strobel T, Swanson L, Cannistra CA. In vivo inhibition of CD44 limits intra abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997;57:1228-32.
4. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011;71:4085-95.
5. Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995;85:2885-99.
6. Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ, Pals ST. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1994;344:1470-2.
7. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP. De novo expression of CD44 and survival in gastric cancer. Lancet. 1993;342:1019-22.
8. Günthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13-24.
9. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U. Expression of CD44 isoforms in renal cell tumors Positive correlation to tumor differentiation. Am J Pathol. 1996;148:453-63.
10. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade clinicopathologic parameters p53 expression and patient survival. J Hepatol. 2000;32:78-84.
11. Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, Breitenecker G. Koelbl H splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol. 1995;57:383-7.
12. Uhl-Steidl M, Muller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O. Prognostic value of CD44 splice variant expression in ovarian cancer. Oncololgy. 1995;52:400-6.
13. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44 cDNA down-regulates expression of overall CD44 isoforms and inhibits tumour growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer. 2001;91:67-75.
14. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet. 1995;345:615-9.
15. Manten-Horst E, Danen EH, Smit L, Snoek M, Le Poole IC, Van Muijen GN, Pals ST, Ruiter DJ. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer. 1995;64:182-8.
16. Ossipov DA. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv. 2010;7:681-703.
17. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5:474-86.
18. Choi KY, Chung H, Hyun K, Hong M, Yoon Y, Kim K, Park JH, Kwon IC, Jeong SY. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31:106-14.
19. Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, Kim SY, Myung SJ, Lee S, Chen X, Kwon IC, Choi K, Jeong SY, Kim K, Park JH. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012;33:6186-93.
20. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92.
21. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62:90-9.
22. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.
23. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58:1532-55.
24. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-26.
25. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2:373-83.
26. Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25:2843-9.
27. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2:8-21.
28. de Belder AN, Wik KO. Preparation and properties of fluorescein-labeled hyaluronate. Carbohydr Res. 1975;44:251-7.
29. Shannon RS, Minakshi N, Nihal A. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-61.
30. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(p) human ovarian carcinoma xenografts. Neoplasia. 2007;9:479-86.
31. Lee H, Mok H, Lee S, Oh YK, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119(2):245-52.
32. Harris EN, Kyosseva SV, Weigel JA, Weigel PH. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem. 2007;282(5):2785-97.
33. Choi KY, Min KH, Na JH, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem. 2009;19(24):4102-7.
34. Kurtzhals P, Larsen C, Johansen M. High performance size-exclusion chromatographic procedure for the determination of fluoresceinyl isothiocyanate dextrans of various molecular masses in biological media. J Chromatogr. 1989;491:117-27.
35. Dacai L, Pearlment E, Diaconu E, Kun G, Hiroshi M, HaqqI S, Sanford M, Willson J, Sun SM. Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc Natl Acad Sci. 1996;93:7832-7.